Exelixis licenses small molecule from Insilico for $80M upfront; Vertex buys GPCR from Septerna
Exelixis is buying into a cancer drug candidate discovered by generative AI from Insilico Medicine, the two companies announced Tuesday.
The Bay Area cancer company is paying Insilico $80 million upfront for ISM3091 — a small molecule that inhibits USP1. The enzyme is an important mediator of DNA damage responses, and is dysregulated in certain cancers. Exelixis is investigating the drug for BRCA-mutated tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.